Protalix BioTherapeutics (PLX) Stock: Why It's Down Today
Updated Oct 19, 2026, 4:00 PM ET · closing price
- Closed at $2.56, -2.29% vs the prior close of $2.62.
- Volume 914.63K shares, 1.1x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
PLX dips 2.3% to $2.56, a 1-month low. Closed at $2.56, -2.29% vs the prior close of $2.62. Day range $2.54–$2.66, opened at $2.63.
PLX daily analysis — what happened
A plain-English, data-only note for every US trading day (today's note updates every 2 hours while the market is open). Newest first; older days stay archived below.
Oct 19, 2026 — PLX dips 2.3% to $2.56, a 1-month low
- Closed at $2.56, -2.29% vs the prior close of $2.62. Day range $2.54–$2.66, opened at $2.63.
- Volume was 914.63K shares, 1.1x its 50-day average of 848.99K.
- Price is -2.0% vs its 50-day average ($2.61) and +7.3% vs its 200-day average ($2.38).
- 52-week range $1.60–$3.19; today's close sits at 60% of that range, 19.7% below the 52-week high.
Oct 16, 2026 — PLX dips 3.0% to $2.62
- Closed at $2.62, -2.96% vs the prior close of $2.70. Day range $2.61–$2.69, opened at $2.70.
- Volume was 1.18M shares, 1.4x its 50-day average of 835.88K.
- Price is +0.4% vs its 50-day average ($2.61) and +10.0% vs its 200-day average ($2.38).
- 52-week range $1.60–$3.19; today's close sits at 64% of that range, 17.9% below the 52-week high.
Oct 15, 2026 — PLX jumps 3.4% to $2.70
- Closed at $2.70, +3.45% vs the prior close of $2.61. Day range $2.62–$2.75, opened at $2.63.
- Volume was 1.14M shares, 1.4x its 50-day average of 823.88K.
- Price is +3.6% vs its 50-day average ($2.61) and +13.6% vs its 200-day average ($2.38).
- 52-week range $1.60–$3.19; today's close sits at 69% of that range, 15.4% below the 52-week high.
Oct 14, 2026 — PLX slides 5.1% to $2.61, a 1-month low on 1.9x normal volume
- Closed at $2.61, -5.09% vs the prior close of $2.75. Day range $2.61–$2.78, opened at $2.73.
- Volume was 1.53M shares, 1.9x its 50-day average of 807.56K — unusually heavy trading.
- Price is +0.4% vs its 50-day average ($2.60) and +10.0% vs its 200-day average ($2.37).
- 52-week range $1.60–$3.19; today's close sits at 64% of that range, 18.2% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — PLX dips 1.1% to $2.75
- Closed at $2.75, -1.08% vs the prior close of $2.78. Day range $2.74–$2.80, opened at $2.80.
- Volume was 966.80K shares, 1.2x its 50-day average of 808.76K.
- Price is +5.9% vs its 50-day average ($2.60) and +16.1% vs its 200-day average ($2.37).
- 52-week range $1.60–$3.19; today's close sits at 72% of that range, 13.8% below the 52-week high.
Oct 12, 2026 — PLX ends flat (+0.0%) to $2.78
- Closed at $2.78, +0.00% vs the prior close of $2.78. Day range $2.71–$2.80, opened at $2.75.
- Volume was 717.00K shares, 0.9x its 50-day average of 819.07K.
- Price is +7.5% vs its 50-day average ($2.59) and +17.6% vs its 200-day average ($2.36).
- 52-week range $1.60–$3.19; today's close sits at 74% of that range, 12.9% below the 52-week high.
Oct 9, 2026 — PLX rises 3.0% to $2.78
- Closed at $2.78, +2.96% vs the prior close of $2.70. Day range $2.69–$2.79, opened at $2.70.
- Volume was 1.20M shares, 1.5x its 50-day average of 800.30K.
- Price is +7.8% vs its 50-day average ($2.58) and +17.9% vs its 200-day average ($2.36).
- 52-week range $1.60–$3.19; today's close sits at 74% of that range, 12.9% below the 52-week high.
Oct 8, 2026 — PLX dips 0.4% to $2.70
- Closed at $2.70, -0.37% vs the prior close of $2.71. Day range $2.61–$2.71, opened at $2.68.
- Volume was 972.80K shares, 1.2x its 50-day average of 792.40K.
- Price is +5.1% vs its 50-day average ($2.57) and +14.7% vs its 200-day average ($2.35).
- 52-week range $1.60–$3.19; today's close sits at 69% of that range, 15.4% below the 52-week high.
Oct 7, 2026 — PLX dips 0.7% to $2.71
- Closed at $2.71, -0.73% vs the prior close of $2.73. Day range $2.68–$2.77, opened at $2.70.
- Volume was 794.50K shares, 1.0x its 50-day average of 784.15K.
- Price is +5.9% vs its 50-day average ($2.56) and +15.4% vs its 200-day average ($2.35).
- 52-week range $1.60–$3.19; today's close sits at 70% of that range, 15.0% below the 52-week high.
Oct 6, 2026 — PLX rises 0.7% to $2.73
- Closed at $2.73, +0.74% vs the prior close of $2.71. Day range $2.65–$2.76, opened at $2.74.
- Volume was 934.70K shares, 1.2x its 50-day average of 776.79K.
- Price is +7.0% vs its 50-day average ($2.55) and +16.5% vs its 200-day average ($2.34).
- 52-week range $1.60–$3.19; today's close sits at 71% of that range, 14.4% below the 52-week high.
Oct 5, 2026 — PLX ends flat (+0.0%) to $2.71
- Closed at $2.71, +0.00% vs the prior close of $2.71. Day range $2.65–$2.74, opened at $2.68.
- Volume was 984.10K shares, 1.3x its 50-day average of 761.36K.
- Price is +6.4% vs its 50-day average ($2.55) and +15.9% vs its 200-day average ($2.34).
- 52-week range $1.60–$3.19; today's close sits at 70% of that range, 15.0% below the 52-week high.
Oct 2, 2026 — PLX rises 1.1% to $2.71
- Closed at $2.71, +1.12% vs the prior close of $2.68. Day range $2.64–$2.72, opened at $2.70.
- Volume was 947.30K shares, 1.3x its 50-day average of 751.39K.
- Price is +6.7% vs its 50-day average ($2.54) and +16.1% vs its 200-day average ($2.33).
- 52-week range $1.60–$3.19; today's close sits at 70% of that range, 15.0% below the 52-week high.
PLX bull case vs bear case (from the data)
- Price is +7.3% vs its 200-day average — above the long-term trend line.
- Insiders made 4 open-market purchases in the last 12 months.
- Price is -2.0% vs its 50-day average — short-term trend is down.
- Annual revenue fell 1.2% in the latest fiscal year (SEC XBRL).
- Latest fiscal-year net income: loss of $6.60M.
PLX latest news & SEC filings
Every SEC filing by or about PLX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 15, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 4, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 4, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 4, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 4, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 4, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 12, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 12, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $19.90M (prior year $15.66M) (+27.1% vs Jun 30, 2025)
- Net income: $3.78M (prior year $164.00K) (+2203.0% vs Jun 30, 2025)
- Diluted EPS: $0.05 (prior year $0.00)
Aug 12, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 29, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jun 25, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Things to know before you trade PLX
- Last results release: Aug 12, 2026 (8-K Item 2.02). Previous ones: May 13, 2026, Mar 18, 2026, Nov 13, 2025. Based on that rhythm, the next report is likely around Nov 11, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.75% (largest 5.1%).
- Liquidity: about 928.64K shares (≈$2.38M) trade per day on average.
- 52-week position: $2.56 vs a range of $1.60–$3.19 (60% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 4 open-market buys, 4 sales; latest: Dror Bashan bought 56,000 shares on Dec 19, 2025.
- Latest filings: 10-Q Aug 12, 2026; 8-K Aug 12, 2026; 8-K Jun 25, 2026.
- Share count: 80.57M shares outstanding (Aug 1, 2026), +1.1% vs a year earlier.
- Listing: NYSE · industry: Biological Products, (No Diagnostic Substances).
PLX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 19, 2026 | 2.63 | 2.66 | 2.54 | 2.56 | 914.63K |
| Oct 16, 2026 | 2.70 | 2.70 | 2.61 | 2.62 | 1.19M |
| Oct 15, 2026 | 2.63 | 2.75 | 2.62 | 2.70 | 1.14M |
| Oct 14, 2026 | 2.73 | 2.78 | 2.61 | 2.61 | 1.53M |
| Oct 13, 2026 | 2.80 | 2.80 | 2.74 | 2.75 | 966.80K |
| Oct 12, 2026 | 2.75 | 2.80 | 2.71 | 2.78 | 717.00K |
| Oct 9, 2026 | 2.70 | 2.79 | 2.69 | 2.78 | 1.20M |
| Oct 8, 2026 | 2.68 | 2.71 | 2.61 | 2.70 | 972.80K |
| Oct 7, 2026 | 2.70 | 2.77 | 2.68 | 2.71 | 794.50K |
| Oct 6, 2026 | 2.74 | 2.76 | 2.65 | 2.73 | 934.70K |
| Oct 5, 2026 | 2.68 | 2.74 | 2.65 | 2.71 | 984.10K |
| Oct 2, 2026 | 2.70 | 2.72 | 2.64 | 2.71 | 947.30K |
| Oct 1, 2026 | 2.77 | 2.77 | 2.60 | 2.68 | 1.59M |
| Sep 30, 2026 | 2.69 | 2.82 | 2.68 | 2.76 | 836.20K |
| Sep 29, 2026 | 2.69 | 2.74 | 2.68 | 2.69 | 898.50K |
| Sep 28, 2026 | 2.71 | 2.72 | 2.61 | 2.69 | 831.80K |
| Sep 25, 2026 | 2.76 | 2.78 | 2.70 | 2.72 | 386.00K |
| Sep 24, 2026 | 2.78 | 2.82 | 2.73 | 2.75 | 302.30K |
| Sep 23, 2026 | 2.84 | 2.85 | 2.77 | 2.80 | 586.10K |
| Sep 22, 2026 | 2.75 | 2.84 | 2.75 | 2.84 | 854.70K |
About Protalix BioTherapeutics
Protalix BioTherapeutics (PLX) is listed on the NYSE and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in HACKENSACK, NJ. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1006281.
PLX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Amos Bar-Shalev | Director | Sep 4, 2026 |
| Dror Bashan | PRESIDENT AND CEO | Sep 4, 2026 |
| Zvi Shmuel Ben | Director | Sep 4, 2026 |
| Pol F Boudes | Director | Sep 4, 2026 |
| Christian Elze | Director | Sep 4, 2026 |
| Eliot Forster | Director | Sep 4, 2026 |
| Gwen A Melincoff | Director | Sep 4, 2026 |
| Aharon Schwartz | Director | Sep 9, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Dror Bashan | PRESIDENT AND CEO | Sep 4, 2026 |
| Gilad Mamlok | Sr. VP and CFO | Apr 27, 2026 |
| Yaron Naos | Sr. VP & COO | Sep 4, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Dec 19, 2025 | Dror Bashan | Buy | 56,000 | $1.81 |
| Dec 19, 2025 | Dror Bashan | Buy | 56,000 | $1.81 |
| Dec 19, 2025 | Dror Bashan | Buy | 56,000 | $1.81 |
| Dec 19, 2025 | Dror Bashan | Buy | 56,000 | $1.81 |
| Nov 18, 2025 | Amos Bar-Shalev | Sale | 168 | $1.87 |
| Nov 18, 2025 | Amos Bar-Shalev | Sale | 168 | $1.87 |
| Nov 18, 2025 | Amos Bar-Shalev | Sale | 168 | $1.87 |
| Nov 18, 2025 | Amos Bar-Shalev | Sale | 168 | $1.87 |
PLX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $52.74M | $-6.60M | -0.08 | $-11.99M |
| Dec 31, 2024 | $53.40M | $2.93M | 0.04 | $8.67M |
| Dec 31, 2023 | $65.49M | $8.31M | 0.09 | $-1.32M |
| Dec 31, 2022 | $47.64M | $-14.93M | -0.31 | $-25.00M |
| Dec 31, 2021 | $38.35M | $-27.58M | -0.62 | $-10.29M |
Latest balance sheet: total assets $110.34M, total liabilities $38.93M, cash $27.42M (as of Jun 30, 2026).
PLX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 12, 2026 | 8-K Item 2.02 (results) | $2.62 |
| May 13, 2026 | 8-K Item 2.02 (results) | $1.93 |
| Mar 18, 2026 | 8-K Item 2.02 (results) | $2.21 |
| Nov 13, 2025 | 8-K Item 2.02 (results) | $1.93 |
| Aug 14, 2025 | 8-K Item 2.02 (results) | $1.52 |
| May 9, 2025 | 8-K Item 2.02 (results) | $1.72 |
| Mar 17, 2025 | 8-K Item 2.02 (results) | $2.45 |
| Nov 14, 2024 | 8-K Item 2.02 (results) | $1.41 |
| Aug 14, 2024 | 8-K Item 2.02 (results) | — |
| May 10, 2024 | 8-K Item 2.02 (results) | — |
| Mar 14, 2024 | 8-K Item 2.02 (results) | — |
| Nov 6, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Biogen (BIIB)Halozyme Therapeutics (HALO)Vaxcyte (PCVX)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)AMD (AMD)Microsoft (MSFT)Intel (INTC)Amazon (AMZN)
More on PLX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 19, 2026, 4:00 PM ET. Filings: SEC EDGAR. Refreshed every 2 hours during US market hours.